You just read:

Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy

News provided by

Viking Therapeutics, Inc.

06 Dec, 2016, 16:05 ET